Skip to main content

Dermatology and Therapy

Ausgabe 4/2024

Inhalt (21 Artikel)

Open Access Review

Novel Topical Treatments for Itch

Rami H. Mahmoud, Omar Mahmoud, Georgia Biazus Soares, Gil Yosipovitch

Open Access Review

Psoriasis and Molecular Target Therapies: Evidence of Efficacy in Preventing Cardiovascular Comorbidities

Luca Potestio, Nello Tommasino, Giuseppe Lauletta, Fabrizio Martora, Matteo Megna

Open Access Original Research

Virtual Learning Decreases the Carbon Footprint of Medical Education

Divya Sharma, Julianne Rizzo, Yvonne Nong, Lilia C. Murase, Sydney Fong, Kenny Lo, Misha Rosenbach, Raja Sivamani, Jenny E. Murase

Open Access Original Research

Maintenance of Investigator’s Static Global Assessment Response with Once-Daily Crisaborole in Participants with Mild to Moderate Atopic Dermatitis

Lawrence F. Eichenfield, Linda F. Stein Gold, Charles Lynde, Lyn Guenther, Shoshana Greenberger, Chia-Yu Chu, Zara Ghodsi, Bonnie Vlahos, Paul Sanders, Amy Cha, Juliana M. Canosa

Open Access Original Research

Effectiveness of Ixekizumab in Chinese Patients with Moderate-Severe Plaque Psoriasis with Special Area Involvement: Subanalysis of a Prospective, Multicenter, Observational Real-World Study

Ying Li, Chengzhi Lv, Lin Dang, Bingjiang Lin, Juan Tao, Chunlei Zhang, Xiaoyong Zhou, Han Ma, Yi Lu, Rong Chen, Jinnan Li, Guanshen Dou, Yunsheng Liang, Yanhua Liang, Yuling Shi

Open Access Original Research

Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus

Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Anna G. Burroni, Andrea Chiricozzi, Paolo Dapavo, Silvia M. Ferrucci, Massimo Gola, Maddalena Napolitano, Michela Ortoncelli, Maria T. Rossi, Claudio Sciarrone, Antonio Costanzo, Alessandra Narcisi

Open Access Original Research

Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies

April Armstrong, Alvaro González-Cantero, Saakshi Khattri, Guilherme Muzy, William N. Malatestinic, Anastasia Lampropoulou, Meghan Feely, Sophia Kyoungah See, Can Mert, Andrew Blauvelt

Open Access Original Research

Current Diagnostic and Therapeutic Practices in Alopecia Areata in Two Mediterranean Countries: A Survey-Based Study

Michela Starace, Francesca Pampaloni, Elisabeth Lazaridou, Eirini Kyrmanidou, Alexander Stratigos, Aimilios Lallas, Alexander Katoulis, Dimitrios Sgouros, Federico Quadrelli, Luca Rapparini, Stephano Cedirian, Francesca Bruni, Lorenzo Ala, Alfredo Rossi, Bianca Maria Piraccini, Zoe Apalla

Open Access Original Research

Utilising SNP Association Analysis as a Prospective Approach for Personalising Androgenetic Alopecia Treatment

Manuel Pacareu Francès, Laura Vila-Vecilla, Valentina Russo, Hudson Caetano Polonini, Gustavo Torres de Souza

Open Access Original Research

Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis

Tiago Torres, Anne Sohrt Petersen, Ulla Ivens, Albert Bosch Vilaro, John Stinson, José Manuel Carrascosa

Open Access Original Research

The Epidemiology of Hospital-Treated Alopecia Areata in Denmark, 1995–2016

Sissel Brandt Toft Sørensen, Prethibha George, Oladayo Jagun, Robert Wolk, Lynne Napatalung, Samuel H. Zwillich, Lars Iversen, Vera Ehrenstein

Open Access Original Research

Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60

Alexander Egeberg, Jason E. Hawkes, Najwa Somani, Russel Burge, Kyoungah See, Gaia Gallo, Missy McKean-Matthews, Melinda Gooderham, George Han, April Armstrong

Open Access Brief Report

Improvements in Psoriasis-Related Work Productivity with Tildrakizumab: Results from a Phase 4 Real-World Study in Patients with Moderate-to-Severe Plaque Psoriasis

Tina Bhutani, John Koo, Jayme Heim, Neal Bhatia, Jacob Mathew, Thomas Ferro, J. Gabriel Vasquez

Open Access Brief Report

Characteristics and Management of Patients with Alopecia Areata and Selected Comorbid Conditions: Results from a Survey in Five European Countries

Sergio Vañó-Galván, Alexander Egeberg, Bianca Maria Piraccini, Simran Marwaha, Catherine Reed, Erin Johansson, Frederick Durand, Anthony Bewley

Open Access Brief Report

Clinical Characteristics and Therapeutic Aspects of Blaschko Linear Psoriasis

Ling Chen, Yufan Cheng, Lu Peng, Xuesong Jia, Guangren Liu, Zhu Shen

Open Access Case Report

Atypical Fibroxanthoma Treated with a Topical Combination of Imiquimod, Tazarotene, and 5-Fluorouracil

William J. Nahm, Evangelos V. Badiavas, Robert S. Kirsner, Carter J. Boyd, Anita A. Arthur, Sean Bae, John Shen

Open Access Case Report

Acute Systemic Toxicity Caused by Topical Application of EMLA Cream on a Leg Ulcer: Case Report and Review of Literature

Sarah Marie Hoffmann, Anna Luisa Hartmann, Pablo Nieratschker, Michael Berthold Mussler, Christoph Mathis Schempp

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.